CORDIS
EU research results

CORDIS

English EN
Improving Genome Editing Efficiency (IMGENE)

Improving Genome Editing Efficiency (IMGENE)

Objective

CRISPR genome editing technology is considered to become the greatest technological improvement in biomedical research since the invention of the polymerase chain reaction 25 years ago and pharmaceutical companies as well as academic research are eager to apply it. However, the efficiency of introducing defined changes into the genome by CRISPR is still low, currently limiting its application in basic research, industry and gene therapy. IMGENE unites expert European research groups of academia and industry to address by innovative and complementary approaches the low efficiency of precise genome editing using CRISPR technology. To our best knowledge, IMGENE is the only concerted approach to tackle the important problem of low genome editing efficiency of CRISPR in a multidisciplinary, intersectorial manner. The IMGENE consortium consisting of 6 academic and 1 industrial beneficiary (AstraZeneca), 2 industrial partners (Taconic; MilliporeSigma), and the patient organization Genetic Alliance, aims to improve the genome editing efficiency of CRISPR by research training of 8 ESRs to unleash the full potential of this technology. Combining complementary knowledge on protein chemistry, molecular biology, cellular biology, viral vectors, transgenic mice, gene therapy, and bioinformatics present in the network, IMGENE will establish novel tools and protocols for improved CRISPR genome editing efficiency that will be of immediate benefit for health and life science research, the pharmaceutical industry, and the application of gene therapy. In addition, IMGENE addresses crucial ethical questions related to the application of genome editing technology in animals, plants, and humans, which have to be solved to gain acceptance by the society. By excellent research training of 8 ESRs on a scientifically and economically highly relevant topic and additional training in transferable skills, IMGENE will educate novel leaders with great career perspectives in industry and academia.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KOBENHAVNS UNIVERSITET

Address

Norregade 10
1165 Kobenhavn

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 580 163,76

Participants (6)

Sort alphabetically

Sort by EU Contribution

Expand all

ASTRAZENECA AB

Sweden

EU Contribution

€ 263 659,32

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 249 216,48

INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC

Portugal

EU Contribution

€ 238 356,36

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 255 374,28

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)

Germany

EU Contribution

€ 249 216,48

USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE

Czechia

EU Contribution

€ 232 422,48

Partners (3)

Sort alphabetically

Expand all

Taconic GmbH

Millipore Sigma

Genetic Alliance

Project information

Grant agreement ID: 765269

Status

Ongoing project

  • Start date

    1 September 2017

  • End date

    31 August 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 068 409,16

  • EU contribution

    € 2 068 409,16

Coordinated by:

KOBENHAVNS UNIVERSITET

Denmark